Efficacy and safety of nab-paclitaxel in metastatic gastric cancer: a meta-analysis - supplementary files

Background: Nab-paclitaxel is formulated to address several limitations of paclitaxel. Methods: A systematic review was done of several databases and a meta-analysis with a random-effects model was conducted to assess the efficacy and safety of nab-paclitaxel in metastatic gastric cancer (MGC). Results: Included studies revealed that nab-paclitaxel provides a 30.4% overall response rate and 65.7% disease control rate in MGC patients. The overall survival was 9.65 months and progression-free survival was 4.48 months, associated with the treatment line and regimen. The highest incidence of grade 3 and higher treatment-related adverse events was for neutropenia (29.9%). Conclusion: Nab-paclitaxel provides better disease response and longer survival with manageable side effects in MGC compared with paclitaxel.

背景：白蛋白结合型紫杉醇（nab-paclitaxel）的研发旨在解决普通紫杉醇的诸多局限性。方法：本研究通过检索多个数据库开展系统综述，并采用随机效应模型进行荟萃分析，以评估白蛋白结合型紫杉醇在转移性胃癌（MGC）中的疗效与安全性。结果：纳入的研究显示，白蛋白结合型紫杉醇在转移性胃癌患者中可达到30.4%的总缓解率与65.7%的疾病控制率。患者的总生存期为9.65个月，无进展生存期为4.48个月，上述指标与治疗线数及治疗方案相关。治疗相关的3级及以上不良事件中，中性粒细胞减少症的发生率最高，达29.9%。结论：相较于普通紫杉醇，白蛋白结合型紫杉醇在转移性胃癌中可实现更优的疾病缓解效果与更长的生存期，且不良反应可控。